Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Last updated: March 24, 2025
Sponsor: University of Calgary
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer Treatment

Treatment

Iohexol

Captopril Tablets

Clinical Study ID

NCT05442463
REB19-0460
  • Ages 18-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

  1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women.

  2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 to 90 years

  • Taking hormones orally or non-orally (either estrogen, progesterone or testosterone)

Exclusion

Exclusion Criteria:

  • Cardiovascular disease (symptoms consistent with myocardial ischemia, previouslydocumented myocardial ischemia, cardiac arrhythmias or valve abnormalities, orabnormal ECG at screening)

  • Cerebrovascular disease (transient ischemic attacks or stroke)

  • History of hypertension (BP>140/90 or use of antihypertensive medications)

  • Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2

  • Diabetes mellitus (defined by history, use of hypoglycaemic agents or a fastingglucose >7mmol/L)

  • Current smoker

  • Previous history of preeclampsia

  • Anabolic steroids, cortical steroids, or non-steroidal anti-inflammatorymedications, or at the discretion of the investigator.

Study Design

Total Participants: 200
Treatment Group(s): 2
Primary Treatment: Iohexol
Phase:
Study Start date:
November 30, 2020
Estimated Completion Date:
November 30, 2025

Study Description

Participants are screened for eligibility.

Study involves a 4.5 hour morning in the lab:

  1. Participants come fasting

  2. IV infusion and blood draws

  3. Non invasive testing - Holter monitor, sphygmocor, bioelectrical impedance, blood pressure checks

Connect with a study center

  • University of Calgary

    Calgary, Alberta T2N 4Z6
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.